| Literature DB >> 35178482 |
Shoichi Masaki1, Tadashi Takahashi2, Toshinori Sahara3, Ryo Endo2, Masayoshi Obana2.
Abstract
BACKGROUND: COVID-19 is associated with an increased risk of venous thromboembolism (VTE), and prophylactic anticoagulation is recommended for the prevention of VTE in COVID-19 patients. We encountered a patient with COVID-19 who developed iliopsoas hematoma (IPH) that was likely caused by prophylactic anticoagulation against VTE; we report the case here because IPH is an important risk in rehabilitation treatment. CASE: The patient was a 73-year-old man with severe COVID-19 who received anticoagulation therapy from the time of admission (day 0). On day 22, decreased hemoglobin levels, muscle weakness in the left lower extremity, and pain on passive movement of the left hip joint were noted. On day 29, computed tomography (CT) was performed and revealed a mass lesion suspicious of a hematoma in the left iliopsoas muscle. On day 36, magnetic resonance imaging (MRI) was carried out to re-evaluate the mass lesion and revealed a multicystic lesion that could also have been an abscess. CT-guided puncture drainage was performed, but no pus-like material was collected; this finding led to a diagnosis of IPH. Subsequent exercise loads were gradually increased while the status of the hematoma was assessed. DISCUSSION: The prevalence of IPH in COVID-19 patients has been reported to be 7.6 cases per 1000 admissions, and the use of anticoagulation is likely to increase the risk of IPH. Because rehabilitative interventions can lead to the discovery or aggravation of IPH, the possibility of IPH should be kept in mind when providing rehabilitation treatment for COVID-19 patients. 2022 The Japanese Association of Rehabilitation Medicine.Entities:
Keywords: abnormal coagulation; exercise load; heparin; infectious diseases; rehabilitation risk management
Year: 2022 PMID: 35178482 PMCID: PMC8811153 DOI: 10.2490/prm.20220004
Source DB: PubMed Journal: Prog Rehabil Med ISSN: 2432-1354
Fig. 1.Plain chest CT findings at admission showing panlobular ground-glass opacities in both lungs.
Laboratory test results at admission
| WBC (103/μL) | 8.2 | Na (mEq/L) | 136 |
| NEUT (%) | 85.6 | K (mEq/L) | 4.6 |
| LYMPH (%) | 5.5 | BUN (mg/dL) | 49 |
| MONO (%) | 8.8 | Cre (mg/dL) | 2.13 |
| EOSINO (%) | 0 | eGFR | 24.8 |
| BASO (%) | 0.1 | TP (g/dL) | 6.5 |
| Hb (g/dL) | 14.8 | Alb (g/dL) | 2.9 |
| PLT (103/μL) | 200 | CRP (mg/dL) | 21.68 |
| PT-INR | 1.02 | CK (U/L) | 314 |
| APTT (s) | 32.4 | BNP (pg/mL) | 63.1 |
| D-dimer (μg/mL) | 2.39 | BS (mg/dL) | 206 |
| AST (U/L) | 78 | HbA1c (%) | 9.6 |
| ALT (U/L) | 38 |
Fig. 2.Time course of respiratory support, rehabilitation treatment, and drug therapy. HFNC: high-flow nasal cannula.
Time course of laboratory test results
| Day | ||||||||||||
| X+4 | X+6 | X+11 | X+15 | X+16 | X+20 | X+22 | X+24 | X+29 | X+36 | X+41 | X+45 | |
| WBC (103/μL) | 12.2 | 11.4 | 13.7 | 15.3 | 18.8 | 17.3 | 16.2 | 10.5 | 14.3 | 8.3 | 10.4 | 10 |
| Hb (g/dL) | 13.5 | 13.7 | 13 | 13.4 | 12.3 | 11.2 | 7.7 | 8.5 | 10.6 | 11.3 | 12.2 | 12.2 |
| PLT (103/μL) | 264 | 242 | 161 | 141 | 174 | 312 | 401 | 493 | 497 | 295 | 229 | 209 |
| PT-INR | 1.09 | 1.13 | 1.08 | |||||||||
| APTT (s) | >100 | 34.6 | 31.4 | 51.2 | 46.3 | 38.2 | 41 | 40.1 | ||||
| D-dimer (μg/mL) | 6.76 | 19.12 | 9.25 | 5.18 | 2.9 | 1.85 | 1.81 | 5.83 | 7.16 | |||
| Alb (g/dL) | 2 | 1.7 | 1.4 | 1.9 | 1.6 | 1.9 | 2.3 | 2.6 | ||||
| CRP (mg/dL) | 8.68 | 5.55 | 9.08 | 10.43 | 10.2 | 10.33 | 16.03 | 6.14 | 3.28 | 1.74 | 1.13 | 1.05 |
| HbA1c (%) | 6.4 | |||||||||||
Time course of FIM scores
| At admission to ICU | At discharge from ICU | At discharge from hospital | ||
| Motor items | Eating | 1 | 1 | 7 |
| Grooming | 1 | 2 | 5 | |
| Bathing | 1 | 1 | 3 | |
| Dressing − upper body | 1 | 1 | 4 | |
| Dressing − lower body | 1 | 1 | 3 | |
| Toileting | 1 | 1 | 2 | |
| Bladder management | 1 | 1 | 7 | |
| Bowel management | 1 | 4 | 7 | |
| Transfer to bed | 1 | 1 | 4 | |
| Transfer to toilet | 1 | 1 | 3 | |
| Transfer to bathroom | 1 | 1 | 1 | |
| Wheelchair | 1 | 1 | 5 | |
| Stairs | 1 | 1 | 1 | |
| Motor items total | 13 | 17 | 52 | |
| Cognitive items | Understanding | 1 | 5 | 7 |
| Expression | 1 | 5 | 7 | |
| Social interaction | 1 | 5 | 7 | |
| Problem solving | 1 | 2 | 7 | |
| Memory | 1 | 2 | 7 | |
| Cognitive items total | 5 | 19 | 35 | |
| Total | 18 | 36 | 87 | |
Fig. 3.Abdominal CT images taken on day 29 showing enlargement of the left iliopsoas and psoas major muscles containing multiple masses.
Fig. 4.MRI (gadolinium contrast-enhanced, T1-weighted, fat-suppressed image) taken on day 37 showing multiple cysts in the left iliopsoas and psoas major muscles.
Fig. 5.MRI (gadolinium contrast-enhanced, T1-weighted, fat-suppressed image) taken before transfer to another hospital (day 58) showing that the hematoma in the left iliopsoas and psoas major muscles had decreased in size.